This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

GE Healthcare’s Somo•vTM Automated Breast Ultrasound System Ranked #1 In Women’s Imaging (Specialty) In 2013 Best In KLAS Awards Report

Stock quotes in this article: GE

GE Healthcare today announced that the somo•v TM INSIGHT System was recognized as the category leader with the highest ranking in Women’s Imaging (Specialty) in the 2013 Best in KLAS Awards: Medical Equipment & Infrastructure Report. The Best in KLAS Awards Report ranked imaging, pharmacy automation and infrastructure vendors. This year, over 180 products were ranked by healthcare providers.

KLAS independently monitors vendor performance through the active participation of thousands of healthcare organizations. KLAS Performance Data represents the opinions of healthcare executives, managers, and clinicians from over 4,500 hospitals and 2,500 clinics, who have rated over 750 products and services from more than 200 vendors.

“Being recognized as the category leader in women’s imaging (Specialty) in the Best in KLAS award report further validates the impact of the somo•v ABUS in the breast cancer screening environment and the early detection of cancer in women with dense breasts. This is particularly gratifying as this recognition of leadership is the result of rankings from customers and users throughout the United States and Canada,” said Anders Wold, President and CEO of GE Ultrasound. “Our commitment to ABUS technology and making it available to more healthcare providers and patients around the world is a reflection of the company’s efforts in tackling breast cancer and our overall $1B investment to advance oncology solutions by 2016.”

Using proprietary technology to automate the ultrasound imaging process, the somo•v ABUS system was developed specifically for the breast cancer screening environment. Demonstrating a 35.7 percent improvement in cancer detection (sensitivity), the somo•v ABUS system is the only ultrasound device approved for breast cancer screening in the United States as an adjunct to mammography for asymptomatic women with dense breast tissue who have not had prior breast intervention.

Rising breast cancer incidence and mortality represent a significant threat across the globe, according to a new global study commissioned by GE Healthcare and co-authored by Bengt Jönsson, Professor in Health Economics at the Stockholm School of Economics. Dense breast tissue not only increases the risk of breast cancer up to 4-6 times, but also makes cancer more difficult to detect using mammography, according to multiple large studies. One study, published in the New England Journal of Medicine, showed mammography sensitivity is reduced by 36 to 38 percent in women with dense breasts, as density masks the appearance of tumors (Boyd, et al, NEJM 2007:356:227-36M). As breast density goes up, the accuracy of mammograms goes down.

Mammography is the most effective tool available for screening women for breast cancer; however, it does not work equally well for all women, particularly those with dense breasts, according to Marc Inciardi, MD, breast imaging radiologist at the University of Kansas Cancer Center in Kansas City and consultant to GE Healthcare. “We needed additional screening tools to improve breast cancer detection in women with dense breasts and ABUS has been proven to be beneficial and is easy to use. Enhancing our breast imaging capabilities without increasing the radiation dose, ABUS has quickly become a useful supplementary breast cancer detection tool in our practice.”

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,804.71 -238.19 -1.40%
S&P 500 1,946.16 -26.13 -1.32%
NASDAQ 4,422.0850 -71.3050 -1.59%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs